Beam Therapeutics
BEAM
224 hedge funds and large institutions have $2.6B invested in Beam Therapeutics in 2022 Q3 according to their latest regulatory filings, with 44 funds opening new positions, 74 increasing their positions, 65 reducing their positions, and 25 closing their positions.
247% more call options, than puts
Call options by funds: $53.9M | Put options by funds: $15.5M
76% more first-time investments, than exits
New positions opened: 44 | Existing positions closed: 25
24% more capital invested
Capital invested by funds: $2.09B → $2.6B (+$509M)
14% more repeat investments, than reductions
Existing positions increased: 74 | Existing positions reduced: 65
9% more funds holding
Funds holding: 205 → 224 (+19)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0.26% less ownership
Funds ownership: 77.81% → 77.55% (-0.26%)
Top Buyers
Top Sellers
| 1 |
Temasek Holdings
Singapore
|
-$62.3M |
| 2 |
State Street
Boston,
Massachusetts
|
-$44.1M |
| 3 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$17.2M |
| 4 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$14.3M |
| 5 |
Millennium Management
New York
|
-$13.2M |
BEAM Hedge Fund Activity: Q3 2022 in Review
224 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Beam Therapeutics (BEAM) for Q3 2022, worth a combined $2.6B — up 24% from $2.09B a quarter earlier.
Buyers outnumbered sellers: 44 funds opened new BEAM positions and 25 closed out — a net gain of 19 holders — while 74 added to existing stakes and 65 trimmed.
The largest buyer was Vanguard Group, adding an estimated $52.9M. The largest seller was Temasek Holdings, cutting an estimated $62.3M.
- 224 institutional investors held Beam Therapeutics (BEAM) as of Q3 2022, up from 205 in Q2 2022.
- Funds reported $2.6B of Beam Therapeutics stock for Q3 2022, up 24% quarter-over-quarter.
- 44 funds opened new Beam Therapeutics positions in Q3 2022 and 25 closed out, a net change of +19 holders.
- The largest Beam Therapeutics buyer in Q3 2022 was Vanguard Group, an estimated $52.9M added.
- The largest Beam Therapeutics seller in Q3 2022 was Temasek Holdings, an estimated $62.3M sold.
Based on aggregated 13F filings for Q3 2022.